Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 15Neoplasm Metastasis 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Endometrial Neoplasms 2Solid Tumors 1PIK3CA-Mutated Cancers 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Metastatic Castration-Resistant Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

pembrolizumab 161Carboplatin 145Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 38sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × inavolisib × Clear all
NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
26 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Hoosier Cancer Research Network

Phase 2 Terminated
52 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡